New article in npj Parkinson’s Disease

Congratulations to Dr Michael Sloth Trabjerg MD, 2N Pharma Co-Founder, CSO and Aalborg University Associate Professor Dr John Dirk Vestergaard Nieland, and collaborators on the publication of their newest article in npj Parkinson’s Disease. The article details their work to investigate the therapeutic effect of modulation of cellular energy generation in in vivo models of Parkinson’s disease, and concludes that inhibition of CPT1A restores motor and non-motor function and alleviates many other Parkinson’s disease markers. This is further support for 2N Pharma’s approach to treating neurodegenerative diseases by targeting mitochondrial dysfunction.

Link to the article: